Novate (Clobetasol Propionate)

Clobetasol propionate binds to glucocorticoid receptors in skin cells, modulating gene expression that suppresses pro‑inflammatory cytokines and mediators. This anti‑inflammatory and immunosuppressive action reduces leukocyte infiltration, edema, and the immune response that drive skin lesions.

The prescribed dose of Novate is determined by the treating clinician based on the severity of the skin condition, the size of the affected area, patient age, and response to therapy. Only a qualified healthcare professional should set the regimen.

Safety data for clobetasol propionate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their physician before using Novate.

To request Novate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Novate contains clobetasol propionate, a high‑potency (class I) corticosteroid, offering stronger anti‑inflammatory effects than medium‑potency agents such as betamethasone dipropionate. It is typically reserved for severe or resistant dermatoses and used for shorter periods to minimize adverse effects.

Store Novate at room temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed when not in use.

Apply a thin layer of Novate to the affected area once or twice daily, as directed by the prescriber. Gently rub it in, avoid contact with eyes, mucous membranes and broken skin, and wash hands after application unless treating the hands.

Serious risks include skin atrophy or thinning with prolonged use, secondary bacterial, fungal or viral infections, and systemic adrenal suppression, especially when applied over large surface areas or under occlusion. Patients should be monitored for these complications.

Novate should be avoided in individuals with known hypersensitivity to clobetasol propionate or any formulation excipients, in skin areas infected with bacteria, fungi or viruses (e.g., herpes simplex), and in children under two years of age unless specifically prescribed.